Congo vs Kyrgyzstan: The number of people with susceptibility test result for rifampicin
Congo
2,015
in 2021
Kyrgyzstan
1,932
in 2021
Congo rank
47th
Kyrgyzstan rank
49th
The number of people with susceptibility test result for rifampicin over time
- Congo
- Kyrgyzstan
How they compare
Congo currently reports 2,015 against 1,932 in Kyrgyzstan, a difference of 83.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Kyrgyzstan ahead.
Congo ranks 47th and Kyrgyzstan ranks 49th of 155 countries.
Across the 2 decades both report, Congo averaged higher in 1 and Kyrgyzstan in 1.
Head to head by decade
| Decade | Congo | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 621 | 2,316 | 1,695 | Kyrgyzstan |
| 2020s | 3,055 | 1,836 | 1,218 | Congo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Congo or Kyrgyzstan?
- Congo, at 2,015 against 1,932 in Kyrgyzstan as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Congo and Kyrgyzstan?
- 83, with Congo ahead.
- How many years of comparable data are there for Congo and Kyrgyzstan?
- 5 years are reported by both, from 2017 to 2021.
- How do Congo and Kyrgyzstan rank globally for the number of people with susceptibility test result for rifampicin?
- Congo ranks 47th and Kyrgyzstan ranks 49th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.